- Home
- FGNX vs MREO Comparison
FGNX vs MREO Comparison
Compare FGNX & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FGNX | MREO |
|---|---|---|
| Founded | 1932 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.1M | 50.3M |
| IPO Year | 2014 | 2017 |
Fundamental Metrics
Financial Performance| Metric | FGNX | MREO |
|---|---|---|
| Price | $7.61 | $0.31 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $35.00 | $1.50 |
| AVG Volume (30 Days) | 108.6K | ★ 1.3M |
| Earning Date | 05-19-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $32,023,000.00 | $500,000.00 |
| Revenue This Year | $650.31 | $5,184.20 |
| Revenue Next Year | N/A | $55.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 20.70 | N/A |
| 52 Week Low | $1.59 | $0.20 |
| 52 Week High | $9.35 | $2.37 |
Technical Indicators
Market Signals| Indicator | FGNX | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 49.10 | 58.33 |
| Support Level | $5.64 | $0.27 |
| Resistance Level | $7.71 | $0.35 |
| Average True Range (ATR) | 0.64 | 0.02 |
| MACD | -0.15 | 0.01 |
| Stochastic Oscillator | 53.68 | 94.27 |
Price Performance
Historical ComparisonAbout FGNX Fundamental Global Inc.
FG Nexus Inc operates through two primary segments: Digital Assets and Merchant Banking, with Digital Assets contributing the majority of revenue. The Company functions as a digital asset treasury, mainly holding Ethereum (ETH) and exploring opportunities in the tokenization of real-world assets, leveraging ETH as the foundation for digital finance, stablecoins, DeFi, and tokenized assets. The Merchant Banking segment offers strategic, administrative, and regulatory support to newly formed SPACs through the Company's SPAC platform.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).